Hyperliquid Strategies Inc Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Hyperliquid Strategies Inc Common Stock trades at $9.34 (market cap $2.02B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Hyperliquid Strategies Inc Common Stock is the larger of the two by market cap, and Hyperliquid Strategies Inc Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hyperliquid Strategies Inc Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PURR | QURE | |
|---|---|---|
Market Cap | $2.02B | $1.48B |
Volume | 9,119,303 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $14.09 | $70.59 |
52-Week Low | $3.10 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.88B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
PURR trades at $10.23, down 1.63% over 24 hours, with a bullish technical signal despite recent weakness. The stock shows extreme profitability with a net income margin of 3,229.83% and has beaten earnings estimates for three consecutive quarters. Recent news highlights institutional activity and positive analyst coverage, with a consensus price target of $19.80 implying significant upside.
The outlook is positive given strong earnings momentum and unanimous analyst buy ratings, but risks include high revenue concentration and potential volatility from its asset-heavy business model. The stock's low P/E ratio of 3.18 suggests undervaluation if profitability sustains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Hyperliquid Strategies is a digital asset treasury company focused on managing a treasury of HYPE tokens, the native digital assets of the Hyperliquid Layer-1 blockchain.
Read more on PURR →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →